Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XENE Stock Forecast 2026-2027
$59.70
Current Price
$5.70B
Market Cap
Buy 20
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XENE Price Targets
+67.5%
To High Target of $100.00
+34.0%
To Median Target of $80.00
-1.9%
To Low Target of $58.58
XENE Price Momentum
+1.9%
1 Week Change
+8.7%
1 Month Change
+70.0%
1 Year Change
+33.2%
Year-to-Date Change
-6.6%
From 52W High of $63.95
+111.8%
From 52W Low of $28.19
📊 TOP ANALYST CALLS
Did XENE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xenon is one of their latest high-conviction picks.
Latest XENE Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, XENE has a bullish consensus with a median price target of $80.00 (ranging from $58.58 to $100.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $59.70, the median forecast implies a 34.0% upside. This outlook is supported by 20 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XENE Analyst Ratings
20
Buy
0
Hold
0
Sell
XENE Price Target Range
Low
$58.58
Average
$80.00
High
$100.00
Current: $59.70
Latest XENE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XENE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 16, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $63.00 |
| Mar 10, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $68.00 |
| Mar 10, 2026 | Deutsche Bank | David Hoang | Buy | Maintains | $90.00 |
| Mar 10, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $64.00 |
| Mar 10, 2026 | HC Wainwright & Co. | Douglas Tsao | Buy | Maintains | $74.00 |
| Mar 9, 2026 | Baird | Brian Skorney | Outperform | Maintains | $97.00 |
| Mar 9, 2026 | Needham | Serge Belanger | Buy | Maintains | $80.00 |
| Feb 27, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $49.00 |
| Feb 27, 2026 | Needham | Serge Belanger | Buy | Maintains | $58.00 |
| Feb 24, 2026 | Wolfe Research | Rudy Li | Outperform | Initiates | $60.00 |
| Jan 9, 2026 | JP Morgan | Tessa Romero | Overweight | Maintains | $62.00 |
| Dec 11, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $48.00 |
| Nov 18, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $60.00 |
| Nov 4, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $44.00 |
| Nov 4, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $58.00 |
| Nov 4, 2025 | Needham | Serge Belanger | Buy | Reiterates | $55.00 |
| Oct 7, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $55.00 |
| Sep 3, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Assumes | $48.00 |
| Sep 2, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $55.00 |
| Aug 12, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $55.00 |
Xenon Pharmaceuticals Inc. (XENE) Competitors
The following stocks are similar to Xenon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xenon Pharmaceuticals Inc. (XENE) Financial Data
Xenon Pharmaceuticals Inc. has a market capitalization of $5.70B with a P/E ratio of -13.7x. The company generates $7.50M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -4,974.3% and return on equity of -51.8%.
Valuation Metrics
Market Cap
$5.70B
Enterprise Value
$4.43B
P/E Ratio
-13.7x
PEG Ratio
-0.2x
Price/Sales
759.6x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-4,974.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.1%
Current Ratio
13.4x
Debt/Equity
1.4x
ROE
-51.8%
ROA
-32.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xenon Pharmaceuticals Inc. (XENE) Business Model
About Xenon Pharmaceuticals Inc.
What They Do
Develops therapeutics for neurological and psychiatric disorders.
Business Model
Xenon Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company generates revenue through the commercialization of its drug candidates, with its lead molecule, azetukalner, currently in Phase 3 trials, targeting conditions like epilepsy and depression.
Additional Information
The company also has a diverse pipeline that includes early-stage potassium and sodium channel modulators for pain management. Headquartered in Burnaby, British Columbia, Xenon aims to address significant unmet medical needs in rare central nervous system conditions and other neurological disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
316
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Country
Canada
IPO Year
2014
Website
www.xenon-pharma.comXenon Pharmaceuticals Inc. (XENE) Latest News & Analysis
Latest News
Quick Summary
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) will present at four investor conferences in Q2 2026, focusing on its neuroscience drug discovery and development efforts.
Why It Matters
Xenon Pharmaceuticals' presentation at multiple investor conferences may boost visibility and interest in the company, potentially impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Xenon Pharmaceuticals will present five abstracts at the AAN Annual Meeting, including Phase 3 results for azetukalner in focal onset seizures and long-term data from the X-TOLE study.
Why It Matters
Positive Phase 3 results and long-term safety data for azetukalner could enhance Xenon Pharmaceuticals' market position and investor confidence, potentially driving stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
23 days ago
Quick Summary
On March 13, 2026, the chief medical officer of Xenon Pharmaceuticals sold 1,410 shares for $78,000, reducing his holdings by 16.63% from 8,479 to 7,069 shares.
Why It Matters
Insider selling can signal a lack of confidence in the company's future, potentially affecting stock price and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
XENE shares rose 20% over three months due to positive phase III results for azetukalner, an epilepsy drug, and advancements in its pipeline, enhancing investor confidence.
Why It Matters
XENE's 20% share increase reflects strong investor confidence due to promising phase III data for azetukalner and positive pipeline developments, indicating potential revenue growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
1 month ago
Quick Summary
Driehaus Capital Management raised its stake in XENE by 369,577 shares in Q4 for $15.52 million, with the position value increasing to $36.03 million due to trading and price appreciation.
Why It Matters
Driehaus Capital's significant stake increase in XENE signals strong confidence in the company's future, which may influence other investors and boost XENE's stock price.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Xenon Pharmaceuticals closed a public offering of 12.2 million shares at $57 each, raising approximately $747.5 million. This includes additional shares and pre-funded warrants.
Why It Matters
Xenon Pharmaceuticals raised $747.5 million through a public offering, enhancing liquidity for R&D and potentially driving future growth, impacting stock valuations and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XENE Stock
What is Xenon Pharmaceuticals Inc.'s (XENE) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Xenon Pharmaceuticals Inc. (XENE) has a median price target of $80.00. The highest price target is $100.00 and the lowest is $58.58.
Is XENE stock a good investment in 2026?
According to current analyst ratings, XENE has 20 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $59.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XENE stock?
Wall Street analysts predict XENE stock could reach $80.00 in the next 12 months. This represents a 34.0% increase from the current price of $59.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xenon Pharmaceuticals Inc.'s business model?
Xenon Pharmaceuticals operates as a clinical-stage biopharmaceutical company, focusing on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company generates revenue through the commercialization of its drug candidates, with its lead molecule, azetukalner, currently in Phase 3 trials, targeting conditions like epilepsy and depression.
What is the highest forecasted price for XENE Xenon Pharmaceuticals Inc.?
The highest price target for XENE is $100.00 from at , which represents a 67.5% increase from the current price of $59.70.
What is the lowest forecasted price for XENE Xenon Pharmaceuticals Inc.?
The lowest price target for XENE is $58.58 from at , which represents a -1.9% decrease from the current price of $59.70.
What is the overall XENE consensus from analysts for Xenon Pharmaceuticals Inc.?
The overall analyst consensus for XENE is bullish. Out of 22 Wall Street analysts, 20 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $80.00.
How accurate are XENE stock price projections?
Stock price projections, including those for Xenon Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 9:42 PM UTC